Background Patients with cancer who are infected with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with …

Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…

Radiation therapy (RT) is an essential component of therapy either curative or palliative
armamentarium in oncology, but its efficacy varies considerably among patients through many …

Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, …

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance
to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

The gut microbiome (GM) plays an important role in shaping systemic immune responses and
influences immune checkpoint inhibitor (ICI) efficacy. Antibiotics worsen clinical outcomes …

The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions
with commensal bacteria, thus reprogramming the tumor microenvironment. In addition…

Background: The gut microbiota has been shown to be an important determinant of the efficacy
of immune checkpoint inhibitions (ICI) in cancer. Several lines of evidence suggest that …